List view / Grid view
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A is for Alzheimer's - the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the fight against this deadly disease
19 October 2016 | By Niamh Louise Marriott, Digital Content Producer
A better understanding of how we could manipulate immune system conditions might aid to develop novel therapies against Alzheimer's, Kizil argues...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Dr Henri Leinonen investigated functional abnormalities of the retina using mouse models of human central nervous system diseases...
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The scientists were able to prove that the β2 subunit of the nicotinic receptor is the direct target of soluble amyloid beta peptide...
25 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The protein, called neuregulin-1, has many forms and functions across the brain and is already a potential target for brain disorders such as Alzheimer's disease, amyotrophic lateral sclerosis and schizophrenia...
11 August 2016 | By University of Manchester
Transgenic mice that develop symptoms of Alzheimer's disease were used with one group of 10 treated with mefenamic acid, and 10 with a placebo. The mice were treated at a time when they had developed memory problems. After one month's treatment, memory loss was completely reversed back to the levels…
28 July 2016 | By Epidarex Capital
Epidarex Capital announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3 inflammasome...
21 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Antibiotic treatment decreases levels of disease-causing plaques, a hallmark of Alzheimer's disease, according to a new study by neuroscientists...
19 July 2016 | By Victoria White, Digital Content Producer
Karen Duff of Columbia University says that learning how tau spreads may lead to therapies that stop the toxic protein from jumping between neurons...
In this whitepaper, ADDF partner with Charles River and an expert advisory panel of academic, industry and government scientists to make recommendations on best practices for animal studies testing investigational AD therapies...
4 July 2016 | By Victoria White, Digital Content Producer
Using a mouse model that mimics the development of Alzheimer’s, scientists have determined the biological “insults” that must occur to cause dementia...
30 June 2016 | By Victoria White, Digital Content Producer
The partnership will allow Probiodrug to utilise Crossbeta’s proprietary technology in support of Probiodrug’s biomarker development activities...
29 June 2016 | By Victoria White, Digital Content Producer
A study suggests efavirenz might be an effective therapy for stimulating cholesterol turnover from the brain and slowing or preventing Alzheimer's disease...
27 June 2016 | By Victoria White, Digital Content Producer
Eisai and UCL have reached the first scientific milestone in their neurodegenerative disease drug discovery and development collaboration...
14 June 2016 | By Victoria White, Digital Content Producer
Researchers from the Babraham Institute have found a way to replicate one of the earliest changes in Alzheimer's disease in a dish...
